arrow
K

Katherine Buzzard

Box Hill Hospital
H指数:20
被引数:2,029

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Characterising Executive Functioning in the Chronic Phase of Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium

特征化自身免疫性脑炎慢性期的执行功能:澳大利亚自身免疫性脑炎联盟的研究

2026-02-260
PRE
Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios

肌无力症患者的离散选择实验协同设计中的形成性研究:选择和优化属性、水平和场景

2025-12-170
PRE
Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes

自身免疫性脑炎中的主观神经心理学缺陷:患者与知情者报告的差异及认知测试结果

2025-10-020
OAAI
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium

急性后自身免疫性脑炎中的主观精神症状:澳大利亚自身免疫性脑炎联盟的研究发现

2025-09-290
OAAI
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis

MGBase:一个用于重症肌无力协作研究的全球性、观察性登记系统

2025-06-040
OAAI
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

一年治疗反应预测复发缓解型多发性硬化患者后续5年的疾病进程

2025-02-010
OAAI
Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis

多发性硬化症数字认知生物标志物的纵向轨迹

2025-02-010
OAAI
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

原发性进行性MS患者亚类的疾病改善治疗和残疾进展: 来自大MS数据网络的结果

2024-12-060
OAAI
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
2024-11-012
OAAI
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

克拉屈滨与芬戈莫德,那他珠单抗,ocrelizumab和阿仑单抗在复发缓解型多发性硬化症中的疗效比较

2024-08-010
PRE
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

常规CSF参数可作为多发性硬化症病程的预测指标: 一项MSBase队列研究

2024-04-030
OA
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
2024-03-074
PRE
Risk of secondary progressive multiple sclerosis after early worsening of disability

残疾早期恶化后继发进行性多发性硬化的风险

2023-07-063
PRE
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

继发性进行性多发性硬化症的风险由地理位置决定,但可以改变

BRAIN
IF11.7
2023-06-275
OAAI
Disability accrual in primary and secondary progressive multiple sclerosis

原发性和继发性进行性多发性硬化症的残疾累积

2023-04-174
OA
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

早期非残疾复发是复发缓解型多发性硬化症患者残疾积累的重要预测因素

2023-02-279
OAAI